Invivyd, Inc. (IVVD): Cash & Equivalents
$226.69M
As of 2025-12-31
$160.08M
As of 2026-06-30
+35.0%
3-year compound annual growth
+14.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $226.69M | +226.9% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $69.35M | -65.4% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $200.64M | +117.9% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $92.08M | -83.0% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $542.22M | +371.5% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $114.99M | n/a | 2022-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $14.68M | -25.7% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $36.79M | +38.1% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $232.19M | +4.1% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $20.99M | -42.4% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
Compare IVVD, PLX, FENC, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗